Possis is committed to expanding beyond AngioJet thrombectomy into the broader thrombus management and endovascular markets. Through the strategic development of value-added, non-AngioJet products that build on our core technologies, we’ll create new paths to growth that leverage our current strengths and broaden our scope and reach.

As a growing medical device company, we have the R&D capabilities, manufacturing capacity, clinical and regulatory expertise, and distribution channels to succeed in new ventures beyond the AngioJet technology platform alone. What’s more, our proven and successful AngioJet technology provides us with the respected presence and customer relationships that will drive new growth and reduce Possis’ reliance on AngioJet thrombectomy market for expansion.

Chronic Total Occlusion (CTO) CTO occurs when an artery has been completely blocked (occluded) for more than 30 days. This difficult-to-treat condition requires long endovascular procedures that carry a low success rate and often result in complications. By employing our platform water-jet technology, we are exploring the development of a new treatment system that, like AngioJet, is quick, safe and effective. At present the total U.S. CTO opportunity is estimated to be more than $500 million.

Atherectomy Atherectomy is the process of removing plaque from blood vessels. Compared to current atherectomy procedures that cut, burn, or grind, Possis is leveraging its AngioJet technology to develop the first water-jet based atherectomy product. Unlike thrombus, which is a sudden blockage, plaque causes a gradual narrowing of the vessel and presents its own unique technical and clinical challenges. Our early stage prototypes for this $650 million estimated market are showing promising results.

Hemostasis patch/access site management Possis’ SafeSeal Patch (pictured above left) was introduced in late fiscal 2006. The topical wound dressing specifically targets the more than 7 million diagnostic and therapeutic endovascular procedures performed annually in the United States. In 2007, we estimate the U.S. market for SafeSeal to be $60 million – and we anticipate it growing to approximately $100 million by 2010.

SafeSeal™ Hemostasis Patch The SafeSeal patch is a topical wound dressing that decreases the time needed to control bleeding from the puncture made into a blood vessel to perform an endovascular procedure.